PMC:7283670 / 43081-43342 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T137","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T138","span":{"begin":123,"end":128},"obj":"Body_part"},{"id":"T139","span":{"begin":170,"end":175},"obj":"Body_part"},{"id":"T140","span":{"begin":230,"end":235},"obj":"Body_part"}],"attributes":[{"id":"A137","pred":"fma_id","subj":"T137","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A139","pred":"fma_id","subj":"T139","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T88","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T89","span":{"begin":170,"end":175},"obj":"Body_part"},{"id":"T90","span":{"begin":230,"end":235},"obj":"Body_part"}],"attributes":[{"id":"A88","pred":"uberon_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A89","pred":"uberon_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A90","pred":"uberon_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T238","span":{"begin":36,"end":38},"obj":"Disease"}],"attributes":[{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T409","span":{"begin":0,"end":5},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T410","span":{"begin":0,"end":5},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T411","span":{"begin":107,"end":110},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T412","span":{"begin":116,"end":119},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T413","span":{"begin":121,"end":128},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T414","span":{"begin":170,"end":175},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T415","span":{"begin":170,"end":175},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T416","span":{"begin":230,"end":235},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T417","span":{"begin":230,"end":235},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T102","span":{"begin":21,"end":24},"obj":"Chemical"}],"attributes":[{"id":"A102","pred":"chebi_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T445","span":{"begin":7,"end":44},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T134","span":{"begin":161,"end":184},"obj":"Phenotype"}],"attributes":[{"id":"A134","pred":"hp_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/HP_0002910"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1092","span":{"begin":21,"end":24},"obj":"Gene"},{"id":"1093","span":{"begin":31,"end":34},"obj":"Gene"},{"id":"1094","span":{"begin":107,"end":110},"obj":"Gene"},{"id":"1095","span":{"begin":116,"end":119},"obj":"Gene"},{"id":"1106","span":{"begin":40,"end":43},"obj":"Gene"},{"id":"1157","span":{"begin":91,"end":99},"obj":"Species"},{"id":"1158","span":{"begin":147,"end":155},"obj":"Species"},{"id":"1315","span":{"begin":161,"end":184},"obj":"Disease"}],"attributes":[{"id":"A1092","pred":"tao:has_database_id","subj":"1092","obj":"Gene:26503"},{"id":"A1093","pred":"tao:has_database_id","subj":"1093","obj":"Gene:653590"},{"id":"A1094","pred":"tao:has_database_id","subj":"1094","obj":"Gene:920"},{"id":"A1095","pred":"tao:has_database_id","subj":"1095","obj":"Gene:925"},{"id":"A1106","pred":"tao:has_database_id","subj":"1106","obj":"Gene:250"},{"id":"A1157","pred":"tao:has_database_id","subj":"1157","obj":"Tax:9606"},{"id":"A1158","pred":"tao:has_database_id","subj":"1158","obj":"Tax:9606"},{"id":"A1315","pred":"tao:has_database_id","subj":"1315","obj":"MESH:D056486"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Blood:\nelevated LDH, AST, ALT, GGT, TB, ALP:\n35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)"}